EP3769781
Stöðug and-IFNAR1 samsetning
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
18.8.2016EP published:
19.4.2023EP application number:
20174805.0
EP translation filed:
5.6.2023Grant published:
15.7.2023EPO information:
European Patent Register
Max expiry date:
17.8.2036Expiry date:
17.8.2026Next due date:
31.8.2026
Title in English:
STABLE ANTI-IFNAR1 FORMULATIONLanguage of the patent:
English
Timeline
Today
18.8.2016EP application
19.4.2023EP Publication
5.6.2023Translation submitted
15.7.2023Registration published
17.8.2026Expires
Owner
Name:
Astrazeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
DEPAZ, RobertoAddress:
Gaithersburg, Maryland 20878, US
Name:
DEJESUS, NatalieAddress:
Gaithersburg, Maryland 20878, US
Name:
BEE, JaredAddress:
Gaithersburg, Maryland 20878, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201562207164 PDate:
19.8.2015Country:
US
Classification
Categories:
A61K 39/00, A61K 39/395, C07K 16/00, C07K 16/18, C07K 16/28, C12P 21/00, C12P 21/08
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 25.8.2023
Expires: 17.8.2024
Payer: Árnason Faktor ehf.
Number: 9
Paid: 9.7.2024
Expires: 17.8.2025
Payer: Árnason Faktor ehf.
Number: 10
Paid: 12.8.2025
Expires: 17.8.2026
Payer: Árnason Faktor ehf.